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Abstract
Acute heart failure (AHF) is the most common primary diagnosis for hospitalized heart dis-
eases in Africa. As increased fatty acid β-oxidation (FAO) during heart failure triggers detri-
mental effects on the myocardium, we hypothesized that trimetazidine (TMZ) (partial FAO
inhibitor) offers cardioprotection under normal and obese-related diabetic conditions. Hearts
were isolated from 12-14-week-old obese male and female diabetic (db/db) mice versus
lean non-diabetic littermates (db/+) controls. The Langendorff retrograde isolated heart per-
fusion system was employed to establish an ex vivo AHF model: a) Stabilization phase—
Krebs Henseleit buffer (10 mM glucose) at 100 mmHg (25 min); b) Critical Acute Heart Fail-
ure (CAHF) phase–(1.2 mM palmitic acid, 2.5 mM glucose) at 20 mmHg (25 min); and c)
Recovery Acute Heart Failure phase (RAHF)–(1.2 mM palmitic acid, 10 mM glucose) at 100
mmHg (25 min). Treated groups received 5 μM TMZ in the perfusate during either the CAHF
or RAHF stage for the full duration of each respective phase. Both lean and obese males
benefited from TMZ treatment administered during the RAHF phase. Sex differences were
observed only in lean groups where the phases of the estrous cycle influenced therapy; only
the lean follicular female group responded to TMZ treatment during the CAHF phase. Lean
luteal females rather displayed an inherent cardioprotection (without treatments) that was
lost with obesity. However, TMZ treatment initiated during RAHF was beneficial for obese
luteal females. TMZ treatment triggered significant recovery for male and obese female
hearts when administered during RAHF. There were no differences between lean and
obese male hearts, while lean females displayed a functional recovery advantage over lean
males. Thus TMZ emerges as a worthy therapeutic target to consider for AHF treatment in
normal and obese-diabetic individuals (for both sexes), but only when administered during
the recovery phase and not during the very acute stages.
Introduction
Cardiovascular diseases (CVD) remain the leading cause of global mortality accounting for
~30% of all deaths worldwide [1, 2]. Future projections also indicate that both developed and
developing nations face a growing CVD burden, e.g. heart failure prevalence is expected to
increase by 25% by 2030 [1]. Moreover, the higher incidence of obesity and diabetes—due to
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poor lifestyle choices and inadequate control of CVD risk factors—will further fuel this grow-
ing burden of disease [2].
Acute heart failure (AHF) is a complex clinical syndrome that varies extensively in terms of
underlying pathophysiologic mechanisms and clinical presentations [3]. AHF results in a 3–8%
in-hospital mortality rate, a 9–13% 60–90 day mortality rate and a 25–30% short term re-hospi-
talization rate; and as re-hospitalizations within one year can reach 50%, this demonstrates the
severity of this disease [4]. Acute heart failure syndromes (AHFS) are most commonly diag-
nosed in US Medicare patients, resulting in hospitalization and significant expenses [5, 6]. By
contrast, acute decompensated heart failure (ADHF) is the most common primary diagnosis in
patients with heart disease admitted to hospitals in Africa [7, 8]. While AHF is usually a disease
of the elderly (mean age 70–72 years) in developed nations [9, 10], it strikes at a mean age of
around 52 years in African countries [11, 12]. Although registries of higher income countries
reveal that women with AHFS are generally older than men [13,14], sub-Saharan Africa women
are on average younger and more prone to de novo AHF compared to men [11].
Co-morbidities may act as a trigger for AHF and also play a contributory role in pathology
onset and progression [15]. For example, a graded pattern manifests when AHF patients are
divided into body mass index (BMI) quartiles, i.e. as BMI increases patients are younger and
display more diabetes. In addition, for the fourth quartile (highest BMIs) more AHF patients
tend to be female [16]. Of note, perturbations of metabolic substrate utilization are strongly
linked to both obesity (with concomitant Type 2 diabetes) and heart failure onset and pro-
gression. For example, increased fatty acid β-oxidation (FAO) together with a concomitant
decrease in glucose oxidation (GO) can elicit detrimental effects within the myocardium by
attenuating cardiac function and potentially resulting in death [17, 18].
As for any acute onset event, diagnosis and treatments for AHFS are generally performed
in parallel fashion. During this process the close monitoring of patients is crucial as any
change(s) in condition may require rapid implementation of a different therapeutic regimen
(s). For further treatment of suspected/confirmed AHFS the immediate goal is to improve
symptoms and to stabilize the hemodynamic condition [19,20]. However, the generic nature
of such interventions shows that current therapies are not specifically designed for AHF. Alter-
native treatment modalities were recently proposed but were generally unsuccessful as it did
not lower re-hospitalization rates or improve patient outcome [21]. Thus an important issue to
be addressed is the relatively slow progress to develop AHF-specific therapies [22, 23].
In light of the apparent lack of success with hemodynamically-related drug regimens, the
current pre-clinical study set out to evaluate whether cardiac metabolic modulation can be
employed as a novel therapeutic approach for AHF treatment. Although studies investigating
the use of metabolic moderators have yielded inconsistent data, Trimetazidine (TMZ) emerges
as a robust therapeutic option as it is a commonly used metabolic modulator that is available
in more than 80 countries [24]. This anti-anginal agent acts by selectively inhibiting long-
chain 3-ketoacyl CoA thiolase (3-KAT), thereby attenuating cardiac FAO and shifting metabo-
lism to GO via the Randle cycle [25, 26]. Although beneficial effects of TMZ were reported
for unspecified, ischemic and non-ischemic HF [27, 28], it remains unclear whether it can
enhance cardiac function within the context of AHF. Due to the robust incidence of obesity
and diabetes (generally associated with higher FAO rates) in individuals suffering from AHF,
we set out to assess TMZ-mediated cardioprotective effects in this sub-group versus lean coun-
terparts subjected to AHF.
This study also examined sex-based differences as the CVD risk of females were underval-
ued in the past due to the misunderstanding that only estrogen is responsible for cardioprotec-
tion in this group [29]. However, this misconception has since been addressed [30,31] and
multiple campaigns have since promoted the inclusion of female subjects in pre-clinical and
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clinical studies. Here the focus is largely on the effects of estrogen and (to a lesser extent) pro-
gesterone on the heart [32–35] and also its impact on energy metabolism. For example, estro-
gen can decrease muscle GO, gluconeogenesis and glycogenolysis while elevating FAO [36].
By contrast, the known effects of progesterone on the heart are less well understood. However,
some found that physiologically high progesterone levels are associated with increased conges-
tive heart failure prevalence [37], while the first clues of its role in energy metabolism only
emerged more recently, i.e. mediating its effects via the progesterone receptor-α to subse-
quently activate PI3-K/AKT-1 and MAPK in addition to increased endothelial nitric oxide
(eNOS) activity and NO production [38, 39].
In light of this, we hypothesized that TMZ acts as a novel cardioprotective agent during
AHF under normal and obese-related diabetic conditions. It is further hypothesized that this
response will vary depending on sex and that the estrous cycle will play a key role in this
instance. To better assess the latter notion we further divided females into the two main phases
of the estrous cycle, i.e. the follicular phase (estrogen predominates) and the luteal phase (pro-
gesterone predominates). The main aims of this study were: (1) to establish a de novo, ex vivo
AHF mouse model; and (2) to evaluate the therapeutic value of TMZ under normal and obese-
related diabetic conditions in both male and female mouse hearts subjected to ex vivo AHF.
We also evaluated the influence of estrous cycle phases (follicular, luteal) on TMZ efficacy to
gain additional insights regarding the nature of potential sex differences.
Methods
Animals and ethics
Animals were treated in agreement with the Guide for the Care and Use of Laboratory Ani-
mals of the National Academy of Science (National Institutes of Health publication No. 85–23,
revised 1996). This study was executed with the approval of the Animal Ethics Committees of
Stellenbosch University (South Africa). For the experimental procedure, 102 male and female
diabetic (db/db) mice (aged 12–14 weeks) and their lean non-diabetic littermates (db/+) were
used; original breeding pairs were purchased from Jackson Laboratories (Bar Harbor, ME).
Mice were housed in the animal housing facility (n = 6 per cage) at Stellenbosch University,
under standard conditions and had ad libitum access to water and standard chow.
Vaginal cytology
The estrous cycle of females (12–14 weeks old) was determined by vaginal smear cytology or
“wet smears” as previously described [40, 41]. As group-housed female mice do not display
reliable regular estrous cycling [42, 43], bedding from young male mice was placed in female
cages for a minimum of 5 days prior to performing estrous phase determination. Vaginal
secretion was collected by inserting a pipette tip (filled with 10 μl saline) into the vaginal open-
ing, taking care not to insert it too deep in order to prevent harming the female. The saline was
injected and the vaginal flush was collected in the same tip which was then transferred to a
clean glass slide (Labstar frosted microscope slides; Lasec Laboratory Solution Provider, Cape
Town South Africa). The unstained material was viewed under a light microscope (YS 100,
Nikon Co., Chiyoda, Tokyo Japan) (without use of condenser lens) under 4x, 10x and 40x
objective lenses. Three distinct cell types were present, i.e. epithelial cells (round and nucle-
ated), cornified epithelial cells (irregular in shape, absence of a nucleus) and leukocytes (black,
small and round). The ratio of cell types in the vaginal flush was used to determine estrous
cycle phases, i.e. proestrus was characterized by the predominance of epithelial cells; estrus by
the majority of cornified epithelial cells; metestrus by the presence of a mixed cell type domi-
nated by leukocytes and diestrus by the bulk of leukocytes.
TMZ treatment for acute heart failure
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Acute heart failure: Retrograde Langendorff heart perfusion
Male and female mice (immediately following estrous phase determination) were anesthetized
by an intramuscular injection of ketamine (100 mg/kg) and xylazine (5 mg/kg). Thereafter
hearts of the 12–14 week old mice were rapidly excised into ice-cold perfusion buffer and
mounted on a cannula connected to the modified Langendorff retrograde perfusion model—
flow from the stabilization phase was immediately commenced. The left atrial appendage was
cut off and a deflated self-made balloon constructed from cling wrap (connected to a distilled
water-filled catheter [Portex Jackson catheter with luer connection (4F), Smiths Medical Inter-
national Ltd., Kent UK]) was placed into the left ventricle via the mitral valve. The balloon was
inflated using an insulin syringe connected to the pressure transducer (Stratham MLT 0380/D,
AD Instruments Inc., Bella Vista, NSW Australia) compatible with the PowerLab System
ML410/W (AD Instruments Inc., Bella Vista, NSW Australia). A pacer was connected to the
right atrial appendage of the heart and set to 400 bpm. A buffer-filled reservoir—correlating to
each phase—was raised around the excised heart to maintain the heart at a stable temperature
of 37.5˚C. The PowerLab System was set to record the following functional parameters: left
ventricular end diastolic pressure (LVEDP), left ventricular end systolic pressure (LVESP), left
ventricular developed pressure (LVDevP) [calculated as LVESP-LVEDP], heart rate, rate pres-
sure product (RPP) calculated as [heart rate x LVDevP] and (dp/dt)max (maximum velocity of
contraction) [calculated as pressure difference in mmH2O/time in sec]. Data were recorded
for each parameter listed and for every animal included in this study. Thereafter the data (for
each animal) were expressed as either a percentage of the baseline or as a percentage of the pre-
vious phase. After this step, the final data presented were derived by averaging such values for
each experimental group.
The mouse ex vivo Langendorff retrograde perfusion model of de novo AHF was modified
from a previously established rat model [44–46]. Each of the three phases (discussed below)
was maintained for 25 minutes, for total protocol duration of 75 minutes. All buffers were fil-
tered through a low protein binding filter (Durapore Polyvinylidene fluoride [PVDF] 0.22 μm,
Merck Millipore Co., Darmstadt Germany) on the day of perfusion. The model consists of
three phases namely (1) stabilization, (2) critical acute heart failure (CAHF), and (3) recovery
acute heart failure (RAHF). The buffer for all three phases was based on mouse Krebs-Hense-
leit buffer (NaCl 118 mM, NaHCO3 24 mM, KCl 4.02 mM, NaH2PO4 1.16 mM, Disodium
EDTA.2H20 0.5 mM, MgCl2.6H20 2.5 mM, CaCl2 3.3 mM), with deviations only in glucose
and FA concentrations. The stabilization phase was perfused at 100 cmH2O perfusion pressure
with glucose (10 mM/L) as the sole substrate. Hearts that did not achieve a stable heart rate of
400 ± 20 beats per minute (bpm) and a left ventricular developed pressure of>20 mmHg were
excluded from the study. The CAHF phase is perfused at a reduced perfusion pressure of 20
cmH2O and here the glucose concentration is decreased to 2.5 mM/L, while introducing 1.2
mM/L FA (palmitic acid conjugated to 3% bovine serum albumin [BSA]) into the buffer. This
phase was allowed to continue without any pacing. For the RAHF phase the perfusion pressure
was restored back to 100 cmH2O with the pacer turned on again. Glucose concentrations were
also restored to 10 mM/L baseline condition, with the high FA content (1.2 mM/L) being main-
tained in the recovery buffer. All buffers were gently gassed with 95% O2/5% CO2 (Afrox, Gau-
teng South Africa) for 20 minutes prior to perfusion and for the duration of the experiment.
TMZ treatment. Control groups were allowed to go through the full protocol without any
interventions. However, treated groups received TMZ (5 μM) (Sigma-Aldrich, St. Louis MO)
in the perfusate in either the CAHF or RAHF stage for the full duration of each respective
phase. The therapeutic dose was selected based on mean plasma TMZ concentrations in a clin-
ical study [47] and translated to an equivalent animal dosage as previously described [48].
TMZ treatment for acute heart failure
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Statistical analysis
Data are expressed as mean ± standard error of the mean (SEM) and were analyzed using
either a one-way or two-way analysis of variance (ANOVA) where appropriate, followed by a
Bonferroni post-hoc test (GraphPad Prism v5, San Diego CA). A value of p 0.05 was consid-
ered significant.
Results
Characterizing the estrous cycle
The different stages of the estrous cycle were initially identified, i.e. the follicular (proestrus
and estrus) and luteal (metestrus and diestrus) ones. Slides prepared from mice in the pro-
estrus phase showed a predominance of nucleated epithelial cells and occasionally some
cornified cells and/or leukocytes were present (Fig 1). During the estrus phase there was a pre-
dominance of cornified squamous epithelial cells that are easily identifiable by its irregular
shape and granular cytoplasm. The metestrus phase was characterized by the presence of
mixed cell types although a predominance of leukocytes occurs, while the diestrus phase is
completely dominated by exceptionally dense depositions of leukocytes (Fig 1). While all four
phases were detected in lean females, obese females did not undergo any follicular phases.
Establishing the ex vivo AHF mouse model
The rapid switch in the perfusion system from the stabilization to the CAHF phase (reflecting
de novo AHF) resulted in a drastic decrease in both RPP (p<0.001) and (dp/dt)max (p<0.001)
versus controls (Fig 2A and 2B). Switching from the CAHF to the RAHF phase (reflecting par-
tial recovery) resulted in modest increases for RPP (p<0.001) and (dp/dt)max (p<0.01) (Fig 2A
and 2B, Table 1). However, the resultant recovery in the RAHF phase was still statistically
lower than the initial baseline for both RPP (p<0.001) and (dp/dt)max (p<0.001). There were
no significant changes in heart rate between the phases, although there was a definite tendency
Fig 1. Stages of the estrous cycle characterized by vaginal cytology. The phases are characterized
by the ratio of cells that are present. Indicated are nucleated epithelial cells (E), cornified squamous
epithelial cells (C) and leucocytes (L). Images represent the vaginal flush of lean females under 4x and 10x
magnification.
https://doi.org/10.1371/journal.pone.0179509.g001
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for higher heart rates in the CAHF phase compared to the baseline. Heart rate during the
RAHF phase was also slightly elevated compared to baseline (not significant), indicating that
the heart sustained damage even though there is some recovery (Table 1). LVEDP decreased
following the switch from baseline to CAHF (p<0.01) and subsequently increased during the
RAHF phase compared to CAHF (p<0.001). There was a tendency for the LVEDP to be higher
during RAHF compared to baseline, although this was not statistically significant. The LVESP
Fig 2. RPP and (dp/dt)max in establishing the ex vivo mouse model of acute heart failure (AHF) in lean
male mice. Data is expressed as a percentage of baseline (n = 6). Data represent the last ten minutes of each
phase. Significance is expressed as **p<0.01; ***p<0.001 versus CAHF; and ###p<0.001 versus RAHF.
RPP: rate pressure product, (dp/dt)max: index of myocardial contraction velocity, CAHF: critical acute heart
failure, RAHF: recovery acute heart failure.
https://doi.org/10.1371/journal.pone.0179509.g002
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followed a similar pattern, although it was lower during RAHF versus the initial baseline
(p<0.05) (Table 1).
TMZ treatment of male hearts subjected to AHF
The control lean males showed a 5.6- and 6.4-fold increase for RPP and (dp/dt)max, respec-
tively, from the previous CAHF phase. TMZ treatment initiated during the CAHF phase did
not lead to any differences in terms of functionality. However, when TMZ treatment was initi-
ated during the RAHF phase this strongly improved RPP and (dp/dt)max values compared to
both control and CAHF treated lean males (Fig 3A and 3B, Table 2). Here data revealed an
impressive 3.2-fold increase in RPP between RAHF-treated and control lean males (p<0.001)
and a similar 2.9-fold increase (p<0.001) versus CAHF-treated lean males. The other signifi-
cant parameters that increased included (dp/dt)max and LVDevP (Fig 3B, Table 2). The obese
males exhibited a similar pattern as for the lean males and recovered similarly during the
RAHF phase (Fig 3A and 3B, Table 3). We found no significant changes when comparing
TMZ treatment for lean versus obese males (Table 4).
TMZ treatment of female hearts subjected to AHF
Females were divided into the two main stages of the estrus cycle, namely the follicular and
luteal phase. However, obese females experienced stasis in the luteal phase. Thus we initially
focused on differences between the phases of the lean animals followed by a comparison of
lean and obese females (luteal phases).
TMZ treatment of lean female (follicular vs. luteal) hearts subjected to AHF. Mouse
hearts from lean females (follicular) that received TMZ treatment during the CAHF phase dis-
played a robust increase in RPP (p<0.05) and LVDevP (p<0.05) compared to control females
when function was assessed during the recovery phase (Fig 4A and 4B, Table 5). When TMZ
treatment was initiated during the RAHF phase then this effect was blunted compared to initi-
ation of treatment during the CAHF phase. Thus TMZ treatment of lean luteal females during
the RAHF phase did not result in any significant changes (Fig 4A and 4B, Table 6). In addition,
there were limited differences between lean luteal and follicular females except for TMZ treat-
ment initiated in the RAHF phase where lean luteal females displayed a much higher RPP
(p<0.05) (Fig 4A).
Table 1. Establishing the ex vivo mouse heart model of AHF (lean male mice).
Parameters Baseline vs.
CAHF
CAHF Phase
(% of Baseline)
CAHF
vs.
RAHF
RAHF Phase
(% of Baseline)
Baseline vs.
RAHF
Heart rate
(%)
ns 274.70 ± 81.42 ns 118.90 ± 12.72 ns
LVDevP
(%)
*** 6.40 ± 4.12 ns 15.23 ± 3.31 ###
LVEDP
(%)
** 65.06 ± 6.89 *** 120.30 ± 6.60 ns
LVESP
(%)
*** 46.47 ± 5.75 *** 86.11 ± 1.61 #
Data from the CAHF and RAHF phases were normalized to baseline and thus the CAHF and RAHF phases data are expressed as a percentage of baseline
(n = 6). Data represent the last ten minutes of each phase. Significance is expressed as **p<0.01; ***p<0.001 vs. CAHF and #p<0.05; ###p<0.001 vs.
RAHF. LVDevP: left ventricular developed pressure; LVEDP: left ventricular end diastolic pressure; LVESP: left ventricular end systolic pressure; CAHF:
critical acute heart failure; RAHF: recovery acute heart failure; ns: not significant.
https://doi.org/10.1371/journal.pone.0179509.t001
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Fig 3. Effect of TMZ treatment on RPP and (dp/dt)max of lean and obese males. (A) RPP (B) (dp/dt)max
(n = 6). Data represent the last ten minutes of the RAHF phase and expressed as a fold recovery from the
previous CAHF phase. Significance is expressed as **p<0.01; ***p<0.001 vs. TMZ at RAHF (lean males);
and #p<0.05; ##p<0.01 vs. TMZ at RAHF (obese males). RPP: rate pressure product; (dp/dt)max; index of
myocardial contraction velocity; CAHF: critical acute heart failure; RAHF: recovery acute heart failure.
https://doi.org/10.1371/journal.pone.0179509.g003
TMZ treatment for acute heart failure
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TMZ treatment of lean versus obese female (luteal) hearts subjected to AHF. The con-
trol obese females showed a lower recovery after AHF compared to lean counterparts (Fig 5A
and 5B). No significant differences were found between lean follicular and luteal females
treated with TMZ (Table 7). However, obese females with TMZ treatment (initiated at RAHF)
responded favorably with a 3.3-fold increase in RPP (p<0.01), a 2.3-fold increase in (dp/dt)max
(p<0.05) and a significant increase in LV developed pressure compared to control obese
females (Fig 5A and 5B, Table 8). When comparing lean and obese luteal females during the
RAHF phase it is evident that lean females consistently displayed a superior improvement in
heart function. For example, the RPP is 3.2-fold (p<0.05) higher versus obese females while
lean females that received TMZ treatment during the RAHF phase displayed a higher (dp/
dt)max (p<0.01) compared to obese females (Fig 5A and 5B, Table 9).
Acute heart failure: Males vs. females
Lean groups. We initially compared lean males with lean females (follicular) during the
recovery phase (RAHF)–without any treatments. Here control lean males showed a 5.6- and
6.4-fold increase in RPP and (dp/dt)max, respectively, from the previous CAHF phase (Fig 6A
and 6B). The lean control follicular females also displayed improved function and to a greater
extent than their male counterparts, although such changes were not statistically significant.
For the TMZ treatment regimens initiated during the CAHF phase, we found that females
exhibited a much higher RPP (p<0.001), (dp/dt)max (p<0.001) and LVDevP (p<0.001) versus
Table 2. The effects of TMZ treatment on lean male hearts subjected to AHF (n = 6).
Treatment group Heart rate (%) Sig. LVDevP (%) Sig.
Control 210.13 ± 127.11 ns 1259.06 ± 485.90 **
***TMZ at CAHF 28.26 ± 1.48 2204.29 ± 355.33
TMZ at RAHF 29.74 ± 2.23 6025.70 ± 654.65
Treatment group LVEDP (%) Sig. LVESP (%) Sig.
Control 201.85 ± 36.57 ns 211.06 ± 43.49 ns
TMZ at CAHF 160.23 ± 9.38 170.36 ± 11.07
TMZ at RAHF 158.26 ± 18.72 171.80 ± 24.07
Data represent the last ten minutes of the RAHF phase and expressed as a percentage of CAHF. Significance is expressed as **p<0.01; ***p<0.001 vs.
TMZ (at RAHF). LVDevP: left ventricular developed pressure; LVEDP: left ventricular end diastolic pressure; LVESP: left ventricular end systolic pressure;
CAHF: critical acute heart failure; RAHF: recovery acute heart failure; Sig.: significance; ns: not significant.
https://doi.org/10.1371/journal.pone.0179509.t002
Table 3. The effects of TMZ treatment on obese male hearts subjected to AHF (n = 6).
Treatment group Heart rate (%) Sig. LVDevP (%) Sig.
Control 31.75 ± 2.85 ns 2411.10 ± 458.16 **
TMZ at CAHF 30.17 ± 2.62 1678.49 ± 470.27
TMZ at RAHF 31.78 ± 2.38 4522.35 ± 742.07
Treatment group LVEDP (%) Sig. LVESP (%) Sig.
Control 142.48 ± 10.43 ns 147.98 ± 11.77 ns
TMZ at CAHF 158.98 ± 15.10 164.74 ± 16.48
TMZ at RAHF 141.43 ± 9.98 147.96 ± 12.18
Data represent the last ten minutes of the RAHF phase and expressed as a percentage of CAHF. Significance is expressed as **p<0.01 vs. TMZ at RAHF.
LVDevP: left ventricular developed pressure; LVEDP: left ventricular end diastolic pressure; LVESP: left ventricular end systolic pressure; CAHF: critical
acute heart failure; RAHF: recovery acute heart failure; Sig.: significance; ns: not significant.
https://doi.org/10.1371/journal.pone.0179509.t003
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lean males (Fig 6A and 6B, Table 10). For the RAHF-treated animals, there were no significant
sex-based differences where only males benefited from TMZ treatment.
We next compared lean males with lean females (luteal) and as before, control males exhib-
ited increased RPP and (dp/dt)max from the previous CAHF phase (Fig 7A and 7B). The con-
trol females (luteal) showed a robust increase for both parameters that was significantly higher
versus control lean males (Fig 7A and 7B, Table 11). However, this increase was not signifi-
cantly different when compared to control follicular females (previously discussed). As for fol-
licular females, luteal females treated with TMZ during the CAHF phase displayed a higher
RPP (p<0.01) (dp/dt)max (p<0.05) and LVDevP (p<0.05) compared to lean males. For TMZ
initiated during the RAHF phase, lean males showed significant improvement vs. controls
although RAHF-treated females still exhibited increased (dp/dt)max (p<0.05) versus lean males
(Fig 7B, Table 11).
Obese groups. Obese females (luteal) treated with TMZ during CAHF did not display sig-
nificant functional improvements as with the lean females (Fig 8A and 8B, Table 12). When
treatment was initiated during the RAHF phase the females showed a significant improvement
but to a similar degree when compared to obese males.
Discussion
We hypothesized that TMZ (partial FAO inhibitor) offers cardioprotection during AHF under
normal and obese-related diabetic conditions and that this may be influenced in a sex-depen-
dent manner. The main findings of this study are: (1) our perfusion system resulted in signifi-
cant decreases in both functional and pressure parameters during the CAHF phase, reflecting
de novo AHF. Moreover, our model reflected partial recovery in the RAHF phase with modest
increases in functional and pressure parameters although this was still significantly lower than
Table 4. Comparison of TMZ effects on hearts subjected to AHF—Isolated from lean and obese males (n = 6).
Control
Lean Obese Sig.
Heart rate
(%)
210.13 ± 127.11 31.75 ± 2.85 ns
LVDevP
(%)
1259.06 ± 485.90 2411.10 ± 458.16 ns
LVEDP
(%)
201.85 ± 36.57 142.48 ± 10.43 ns
LVESP
(%)
211.06 ± 43.49 147.98 ± 11.77 ns
TMZ at CAHF TMZ at RAHF
Lean Obese Sig. Lean Obese Sig.
Heart rate
(%)
28.26 ± 1.48 30.17 ± 2.62 ns 29.74 ± 2.23 31.78 ± 2.38 ns
LVDevP
(%)
2204.29 ± 355.33 1678.49 ± 470.27 ns 6025.70 ± 654.65 4522.35 ± 742.07 ns
LVEDP
(%)
160.23 ± 9.38 158.98 ± 15.10 ns 158.26 ± 18.72 141.43 ± 9.98 ns
LVESP
(%)
170.36 ± 11.07 164.74 ± 16.48 ns 171.80 ± 24.07 147.96 ± 12.18 ns
Data represent the last ten minutes of the RAHF phase and expressed as a percentage of CAHF. LVDevP: left ventricular developed pressure; LVEDP: left
ventricular end diastolic pressure; LVESP: left ventricular end systolic pressure; CAHF: critical acute heart failure; RAHF: recovery acute heart failure; Sig.:
significance; ns: not significant.
https://doi.org/10.1371/journal.pone.0179509.t004
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baseline values; (2) lean (db/+) females showed normal estrous cycle phases namely proestrus,
estrus (follicular phase), metestrus and diestrus (luteal phase) while obese females (db/db) did
not undergo the follicular phases (proestrus and estrus); and (3) TMZ treatment resulted in
Fig 4. Effect of TMZ treatment on RPP and (dp/dt)max of lean females (follicular and luteal phase). (A)
RPP (B) (dp/dt)max (n = 6). Data represent the last ten minutes of the RAHF phase and expressed as a fold
recovery from the previous CAHF phase. Significance is expressed as *p<0.05 vs. control lean follicular
females; and #p<0.05 vs. TMZ at RAHF (lean follicular females). RPP: rate pressure product; (dp/dt)max:
index of myocardial contraction velocity; CAHF: critical acute heart failure; RAHF: recovery acute heart failure.
https://doi.org/10.1371/journal.pone.0179509.g004
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negligible changes to functional parameters during the CAHF phase, although significant
results were obtained in terms of recovery function during the RAHF phase. Lean and obese
males responded equally well to TMZ treatment. However, lean females (follicular and luteal
phases) responded in distinct fashion, while obesity influenced females’ response to TMZ
administration. Due to the unique response pattern of the different estrous phases, sex differ-
ences were present only in lean groups.
To establish an ex vivo mouse AHF model we began by modifying a previous experimental
system of acutely underperfused rat hearts where AHF was simulated by decreasing coronary
perfusion pressure [44–46]. This model is representative of hypotensive AHF patients who
present with hypoperfusion, cardiogenic shock and low blood pressure [15, 20, 49]. Lower
pressure upon admission is inversely correlated with in-hospital mortality [50]. In agreement
with the original model, de novo AHF is induced in the isolated heart by decreasing the per-
fusion pressure from 100 cm to 20 cmH2O and by altering metabolic substrates in the perfus-
ate in order to 1) simulate circulating metabolite conditions of HF patients and 2) promote
the upregulation of FA utilization during heart failure. We therefore introduced elevated FA
(1.2 mM/L palmitic acid conjugated to 3% BSA) [51, 52] and decreased the glucose concen-
tration from 10 to 2.5 mM/L [53]. This perfusion system resulted in profound decreases in
both functional and pressure parameters during the CAHF phase reflecting de novo AHF
(Fig 2A and 2B and Table 1). The recovery phase was similarly manipulated by restoring the
perfusion pressure back to 100 cmH2O, restoring glucose to baseline levels (10 mM/L) and by
Table 5. Effect of TMZ treatment during the RAHF phase (lean follicular females) (n = 6).
Treatment group Heart rate (%) Sig. LVDevP (%) Sig.
Control 30.21 ± 4.14 ns 2875.81 ± 725.74
*TMZ at CAHF 27.94 ± 3.51 8049.63 ± 1961.21
TMZ at RAHF 23.93 ± 2.00 4918.75 ± 762.73
Treatment group LVEDP (%) Sig. LVESP(%) Sig.
Control 140.87 ± 9.40 ns 149.10 ± 10.88 ns
TMZ at CAHF 139.35 ± 24.49 152.26 ± 30.49
TMZ at RAHF 137.35 ± 3.71 145.29 ± 4.73
Data represent the last ten minutes of the RAHF phase and expressed as a percentage of CAHF. Significance is expressed as *p<0.05 vs. control.
LVDevP: left ventricular developed pressure; LVEDP: left ventricular end diastolic pressure; LVESP: left ventricular end systolic pressure; CAHF: critical
acute heart failure; RAHF: recovery acute heart failure; Sig.: significance; ns: not significant.
https://doi.org/10.1371/journal.pone.0179509.t005
Table 6. Effect of TMZ treatment during the RAHF phase (lean luteal females) (n = 6).
Treatment group Heart rate (%) Sig. LVDevP (%) Sig.
Control 33.55 ± 4.86 ns 6116.62 ± 1675.88 ns
TMZ at CAHF 34.18 ± 5.60 6202.00 ± 1064.64
TMZ at RAHF 27.31 ± 1.41 9475.80 ± 1807.90
Treatment group LVEDP (%) Sig. LVESP (%) Sig.
Control 179.64 ± 10.82 ns 199.59 ± 13.44 ns
TMZ at CAHF 176.24 ± 43.51 194.08 ± 51.29
TMZ at RAHF 134.06 ± 4.27 147.00 ± 6.88
Data represent the last ten minutes of the RAHF phase and is expressed as a percentage of CAHF. LVDevP: left ventricular developed pressure; LVEDP:
left ventricular end diastolic pressure; LVESP: left ventricular end systolic pressure; CAHF: critical acute heart failure; RAHF: recovery acute heart failure;
Sig.: significance; ns: not significant.
https://doi.org/10.1371/journal.pone.0179509.t006
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maintaining the high FA content. The model reflected partial recovery during the RAHF
phase (Fig 2A and 2B and Table 1) with modest increases in functional and pressure parame-
ters that were still significantly lower than baseline values.
Fig 5. Effect TMZ treatment on RPP and (dp/dt)max (lean vs. obese females). (A) RPP (B) (dp/dt)max
(n = 6). Data represent the last ten minutes of the RAHF phase and expressed as a fold recovery from the
previous CAHF phase. Significance is expressed as *p<0.05; **p<0.01 vs. control obese females. RPP: rate
pressure product; (dp/dt)max: index of myocardial contraction velocity; CAHF: critical acute heart failure;
RAHF: recovery acute heart failure.
https://doi.org/10.1371/journal.pone.0179509.g005
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In order to evaluate whether the estrous cycle may impact on TMZ efficacy during an AHF
event, the different phases of the estrous cycle were initially investigated by vaginal cytology
[40, 41]. The short estrous cycle (lasting 4–5 days) makes the mouse an ideal model to investi-
gate influences of the reproductive cycle. After exposing the females to male pheromones to
ensure regular cycling [42, 43], lean (db/+) females showed normal estrous cycle phases (Fig 1)
namely proestrus, estrus (follicular phase), metestrus and diestrus (luteal phase). However,
obese females (db/db) did not undergo the follicular phases (proestrus and estrus), but rather
displayed metestrus and diestrus acyclicity, a phenomenon common in this transgenic mouse
strain [54–56].
Table 7. Comparison of TMZ effects on hearts subjected to AHF—Lean follicular vs. luteal females (n = 6).
Control
Parameters Follicular Luteal Sig.
Heart rate
(%)
30.21 ± 4.14 33.55 ± 4.86 ns
LVDevP
(%)
2875.81 ± 725.74 6116.62 ± 1675.88 ns
LVEDP
(%)
140.87 ± 9.40 179.64 ± 10.82 ns
LVESP
(%)
149.10 ± 10.88 199.59 ± 13.44 ns
TMZ at CAHF TMZ at RAHF
Follicular Luteal Sig. Follicular Luteal Sig.
Heart rate
(%)
27.94 ± 3.51 34.18 ± 5.60 ns 23.93 ± 2.00 27.31 ± 1.41 ns
LVDevP
(%)
8049.63 ± 1961.21 6202.00 ± 1064.64 ns 4918.75 ± 762.73 9475.80 ± 1807.90 ns
LVEDP
(%)
139.35 ± 24.49 176.24 ± 43.51 ns 137.35 ± 3.71 134.06 ± 4.27 ns
LVESP
(%)
152.26 ± 30.49 194.08 ± 51.29 ns 145.29 ± 4.73 147.00 ± 6.88 ns
Data represent the last ten minutes of the RAHF phase and expressed as a percentage of CAHF. LVDevP: left ventricular developed pressure; LVEDP: left
ventricular end diastolic pressure; LVESP: left ventricular end systolic pressure; CAHF: critical acute heart failure; RAHF: recovery acute heart failure; Sig.:
significance; ns: not significant.
https://doi.org/10.1371/journal.pone.0179509.t007
Table 8. Effect of TMZ treatment on hearts subjected to AHF—Obese luteal females (n = 6).
Treatment group Heart rate (%) Sig. LVDevP (%) Sig.
Control 38.49 ± 10.56 ns 1725.24 ± 397.04
**TMZ at CAHF 36.99 ± 3.84 3199.25 ± 743.72
TMZ at RAHF 32.55 ± 2.48 5400.37 ± 887.21
Treatment group LVEDP (%) Sig. LVESP (%) Sig.
Control 574.86 ± 308.07 ns 521.49 ± 240.36 ns
TMZ at CAHF 140.93 ± 11.62 145.23 ± 12.91
TMZ at RAHF 126.83 ± 7.53 132.12 ± 9.01
Data represent the last ten minutes of the RAHF phase and expressed as a percentage of CAHF. Significance is expressed as **p<0.01 versus control.
LVDevP: left ventricular developed pressure; LVEDP: left ventricular end diastolic pressure; LVESP: left ventricular end systolic pressure; CAHF: critical
acute heart failure; RAHF: recovery acute heart failure; Sig.: significance; ns: not significant.
https://doi.org/10.1371/journal.pone.0179509.t008
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Our results showed that lean and obese males recovered in a similar manner at both treat-
ment time points, i.e. TMZ treatment during the CAHF and RAHF phases, respectively (Fig
3A and 3B). This finding is in accordance to a study performed in streptozotocin-induced dia-
betic rats, where they also found no hemodynamic (peak systolic pressure, end diastolic pres-
sure and dp/dtmax) differences between non-diabetic and diabetic groups [57]. Groups
receiving TMZ during the CAHF phase showed no statistical differences in heart function dur-
ing their recovery as was expected (Table 13); TMZ treatment during the CAHF phase would
partially inhibit 3-KAT and consequently increase glucose utilization [25, 58, 59]. However,
during the CAHF phase glucose availability is exceptionally low and TMZ treatment shifts
metabolism away from the only plentiful metabolite available to the heart. At this point there
may be a neutralizing or even a possible counter-effect of TMZ treatment during the CAHF
phase [60, 61].
Treatment during the RAHF phase, however, resulted in significant functional recovery
(Tables 2 and 3). Metabolic therapies (e.g. TMZ) are extensive areas of research and have been
successful for CVD treatment, with the latter attributed to the promotion of glucose utilization
restoring homeostasis and alleviating the detrimental effect of increased FAO [26, 62, 63, 64,
65]. Liu et al. (2016) showed that TMZ administration decreased myocardial infarction in
mice by significantly activating AMPK and ACC and by shifting the metabolism from FAO to
GO [66]. TMZ also increased mechanical heart function in db/db mice by attenuating FAO-
mediated lipotoxicity and oxidative stress, and also suppressing and preventing the develop-
ment of diabetic cardiomyopathy [67,68]. This was confirmed in obese humans, where TMZ
improved myocardial efficiency by decreasing FAO [69]. Our results also demonstrate that
obesity does not influence TMZ efficacy for AHF treatment in male mice (Fig 3A and 3B and
Table 4). However, some reported contrarian findings, i.e. failing hearts being more dependent
on FFA availability. For example, studies on chronic failing hearts and cardiomyopathic heart
Table 9. Comparison of TMZ effects on hearts subjected to AHF—Lean vs. obese females (luteal) (n = 6).
Control
Parameters Lean Obese Sig.
Heart rate
(%)
33.55 ± 4.86 38.49 ± 10.56 ns
LVDevP
(%)
6116.62 ± 1675.88 1725.24 ± 397.04 *
LVEDP
(%)
179.64 ± 10.82 574.86 ±308.07 ns
LVESP
(%)
199.59 ± 13.44 521.49 ± 240.36 ns
TMZ at CAHF TMZ at RAHF
Lean Obese Sig. Lean Obese Sig.
Heart rate
(%)
34.18 ± 5.60 36.99 ± 3.84 ns 27.31 ± 1.41 32.55 ± 2.48 ns
LVDevP
(%)
6202.00 ± 1064.64 3199.25 ± 743.72 ns 9475.80 ± 1807.90 5400.37 ± 887.21 ns
LVEDP
(%)
176.24 ± 43.51 140.93 ± 11.62 ns 134.06 ± 4.27 126.83 ± 7.53 ns
LVESP
(%)
194.08 ± 51.29 145.23 ± 12.91 ns 147.00 ± 6.88 132.12 ± 9.01 ns
Data represent the last ten minutes of the RAHF phase and expressed as a percentage of CAHF. Significance is expressed as *p<0.05 vs. lean females.
LVDevP: left ventricular developed pressure; LVEDP: left ventricular end diastolic pressure; LVESP: left ventricular end systolic pressure; CAHF: critical
acute heart failure; RAHF: recovery acute heart failure; Sig.: significance; ns: not significant.
https://doi.org/10.1371/journal.pone.0179509.t009
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Fig 6. Effect of TMZ treatment on RPP and (dp/dt)max of lean males vs. lean females (follicular). (A)
RPP (B) (dp/dt)max (n = 6). Data represent the last ten minutes of the RAHF phase and expressed as a fold
recovery from the previous CAHF phase. Significance is expressed as **p<0.01; ***p<0.001 vs. TMZ-
treated lean males (initiated during RAHF); and #p<0.05; ###p<0.001 vs. TMZ-treated lean males (initiated
TMZ treatment for acute heart failure
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failure showed that decreased FFA during HF negatively impacts on both myocardial effi-
ciency and energy metabolism [60, 61]. Together these data show that the degree of FAO inhi-
bition is crucial to ensure sufficient availability of fuel substrates to still allow for myocardial
ATP generation and adequate contractile function. Here TMZ as a well-known partial FAO
inhibitor seems to match these criteria quite well.
Lean females in the two different phases of the estrous cycle responded in unique ways (Fig
4A and 4B). Here lean follicular females recovered optimally when treated with TMZ during
the CAHF phase, unlike when there was no significant recovery when the hearts were treated
during the RAHF phase (Table 6). The lean luteal females were the only group to exhibit inher-
ent superior functional recovery and were also the only group that was not significantly
affected by TMZ treatment for any of the treatment time points (Table 6). This led us to con-
clude that this treatment difference may be due to the effect of sex hormones, i.e. the follicular
phase (dominated by estrogen) and the luteal phase (characterized by progesterone) [40–42,
70]. The lean follicular females was the only group to show significant recovery when TMZ
was administered during the CAHF phase. As previously discussed, the model employed shifts
metabolism towards FAO during CAHF, but TMZ treatment would encourage less desirable
utilization of glucose that is severely decreased (Table 13). We speculate that the beneficial
effects of TMZ could be via estrogen increasing FAO and decreasing glucose utilization [36],
thus allowing the myocardium to utilize the high FAs during this phase. In support, females
seem to be better adapted to utilize FA and may also be protected against increased FA levels
compared to males [35].
during CAHF). RPP: rate pressure product; (dp/dt)max: index of myocardial contraction velocity; CAHF: critical
acute heart failure; RAHF: recovery acute heart failure.
https://doi.org/10.1371/journal.pone.0179509.g006
Table 10. Comparison of TMZ effects on hearts subjected to AHF—Lean males vs. lean females (follicular) (n = 6).
Control
Parameters Males Females Sig.
Heart rate
(%)
210.13 ± 127.11 30.21 ± 4.14 ns
LVDevP
(%)
1259.06 ± 485.90 2875.81 ± 725.74 ns
LVEDP
(%)
201.85 ±36.57 140.87 ± 9.40 ns
LVESP
(%)
211.06 ± 43.49 149.10 ± 10.88 ns
TMZ at CAHF TMZ at RAHF
Males Females Sig. Males Females Sig.
Heart rate
(%)
28.26 ± 1.48 27.94 ± 3.51 ns 29.74 ± 2.23 23.93 ± 2.00 ns
LVDevP
(%)
2204.29 ± 355.33 8049.63 ± 1961.21 *** 6025.70 ± 654.65 4918.75 ± 762.73 ns
LVEDP
(%)
160.23 ± 9.38 139.35 ± 24.49 ns 158.26 ± 18.72 137.35 ± 3.71 ns
LVESP
(%)
170.36 ± 11.07 152.26 ± 30.49 ns 171.80 ± 24.07 145.29 ± 4.73 ns
Data represent the last ten minutes of the RAHF phase and is expressed as a percentage of CAHF. Significance is expressed as ***p<0.001 vs. lean
males. LVDevP: left ventricular developed pressure; LVEDP: left ventricular end diastolic pressure; LVESP: left ventricular end systolic pressure; CAHF:
critical acute heart failure; RAHF: recovery acute heart failure; Sig.: significance; ns: not significant.
https://doi.org/10.1371/journal.pone.0179509.t010
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Fig 7. Effect of TMZ treatment on RPP and (dp/dt)max of lean males vs. lean females (luteal). (A) RPP
(B) (dp/dt)max (n = 6). Data represent the last ten minutes of the RAHF phase and expressed as a fold
recovery from the previous CAHF phase. Significance is expressed as *p<0.05; **p<0.01; ***p<0.001 vs.
TMZ at RAHF lean males, #p<0.05; ##p<0.01 vs. TMZ at CAHF lean males; and $<0.05 vs. control lean
males. RPP: rate pressure product; (dp/dt)max: index of myocardial contraction velocity; CAHF: critical acute
heart failure; RAHF: recovery acute heart failure.
https://doi.org/10.1371/journal.pone.0179509.g007
TMZ treatment for acute heart failure
PLOS ONE | https://doi.org/10.1371/journal.pone.0179509 June 20, 2017 18 / 27
Our results revealed that the lean luteal females did not respond to TMZ treatment.
Research in sex differences in pharmacokinetics and pharmacodynamics [71–72] demon-
strated that increased sex hormones in women can alter hepatic enzyme activities leading to
fluctuations in drug accumulation and/or elimination. Drug metabolism can be altered during
the latter stages of the luteal phase as estrogen is a substrate for cytochrome P450, family 3,
subfamily A (CYP3A) [72,73]. This may explain the lack of response to TMZ in our model
as the biotransformation of TMZ is speculated to involve isoenzymes of CYP3A [74,75] The
findings generated in this study also demonstrate that lean luteal females possess an inherent
“coping mechanism” to better tolerate the AHF event, despite the lack of response to TMZ
treatment. This could be attributed to the protective effects of progesterone on the cardiovas-
cular system [76], e.g. it can assist in cardiac repair by enhancing fibroblast regeneration and
differentiation [77]. Moreover, progesterone displays greater counter-regulatory responses in
response to adrenergic stimulae [78], i.e. it can antagonize vasoconstriction [79], is associated
with increased blood flow [80] and can decrease arrhythmias and the risk of sudden cardiac
death [81]. We propose that any of these factors could influence the apparent innate protection
observed in the lean luteal females. Intriguingly, this inherent cardioprotection is lost with
obesity in luteal females across all the treatment groups (Fig 5A and 5B and Table 9). Here
obese females exhibited the same treatment pattern as their lean counterparts, but at lower val-
ues (Fig 5A and 5B and Table 8). Furthermore, obese luteal females responded to TMZ treat-
ment in the same manner as the males and benefitted only when it was added during the
RAHF phase. We speculate that the treatment effect in females may be affected by the degree
of obesity as obese female mice displayed a 20% increase in body weight compared to 10% for
males [55]. In addition, specific sex differences in body fat content and protein binding can
affect distribution of drugs [71, 82].
Table 11. Comparison of TMZ effects on hearts subjected to AHF—Lean males vs. lean females (luteal) (n = 6).
Control
Parameters Males Females Sig.
Heart rate
(%)
210.13 ± 127.11 33.55 ± 4.86 ns
LVDevP
(%)
1259.06 ± 485.90 6116.62 ± 1675.88 *
LVEDP
(%)
201.85 ± 36.57 179.64 ± 10.82 ns
LVESP
(%)
211.06 ± 43.49 199.59 ± 13.44 ns
TMZ at CAHF TMZ at RAHF
Males Females Sig. Males Females Sig.
Heart rate
(%)
28.26 ± 1.48 34.18 ± 5.60 ns 29.74 ± 2.23 27.31 ± 1.41 ns
LVDevP
(%)
2204.29 ± 355.33 6202.00 ± 1064.64 ns 6025.70 ± 654.65 9475.80 ± 1807.90 ns
LVEDP
(%)
160.23 ± 9.38 176.24 ± 43.51 ns 158.26 ± 18.72 134.06 ± 4.27 ns
LVESP
(%)
170.36 ± 11.07 194.08 ± 51.29 ns 171.80 ± 24.07 147.00 ± 6.88 ns
Data represent the last ten minutes of the RAHF phase and expressed as a percentage of CAHF. Significance is expressed as *p<0.05. LVDevP: left
ventricular developed pressure; LVEDP: left ventricular end diastolic pressure; LVESP: left ventricular end systolic pressure; CAHF: critical acute heart
failure; RAHF: recovery acute heart failure; Sig.: significance; ns: not significant.
https://doi.org/10.1371/journal.pone.0179509.t011
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Our results revealed that sex differences in TMZ efficacy as a therapy for AHF is only pres-
ent in lean groups (Figs 6 and 7 and Tables 10 and 11). There were no differences in functional
recovery between obese males and females (Fig 8A and 8B and Table 12), showing that obesity
is detrimental to both sexes. Sex differences are present between the lean males, and both fol-
licular and luteal lean females. Sex differences in pharmacokinetics and pharmacodynamics is
a common and prevailing phenomenon and elicited considerable interest [72–73]. Alterations
Fig 8. Effect of TMZ treatment on RPP and (dp/dt)max of obese males and females (luteal). (A) RPP (B)
(dp/dt)max (n = 6). Data represent the last ten minutes of the RAHF phase and expressed as a fold recovery
from the previous CAHF phase. Significance is expressed as *p<0.05, **p<0.01 vs. TMZ at RAHF for obese
males; and #p<0.05, ##p<0.01 vs. TMZ at RAHF for obese females. RPP: rate pressure product; (dp/dt)max:
index of myocardial contraction velocity; CAHF: critical acute heart failure; RAHF: recovery acute heart failure.
https://doi.org/10.1371/journal.pone.0179509.g008
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can arise due to sex differences in drug absorption (gastric and hepatic enzyme activities,
transporter proteins, and handling of drugs or metabolites), drug distribution (body fat com-
position and cardiac output), drug metabolism (cytochrome P450 group, hepatic and extra-
hepatic metabolism) and drug elimination. We propose that the distinct sex differences found
Table 12. Comparison of TMZ effects on hearts subjected to AHF–obese males vs. obese females (luteal) (n = 6).
Control
Parameters Males Females Sig.
Heart rate
(%)
31.75 ± 2.85 38.49 ± 10.56 ns
LVDevP
(%)
2411.10 ± 458.16 1725.24 ± 397.04 ns
LVEDP
(%)
142.48 ± 10.43 574.86 ± 308.07 ns
LVESP
(%)
147.98 ± 11.77 521.49 ± 240.36 *
TMZ at CAHF TMZ at RAHF
Males Females Sig. Males Females Sig.
Heart rate
(%)
30.17 ± 2.62 36.99 ± 3.84 ns 31.78 ± 2.38 32.55 ± 2.48 ns
LVDevP
(%)
1678.49 ± 470.27 3199.25 ± 743.72 ns 4522.35 ± 742.07 5400.37 ± 887.21 ns
LVEDP
(%)
158.98 ± 15.10 140.93 ± 11.62 ns 141.43 ± 9.98 126.83 ± 7.53 ns
LVESP
(%)
164.74 ± 16.48 145.23 ± 12.91 ns 147.96 ± 12.18 132.12 ± 9.01 ns
Data represent the last ten minutes of the RAHF phase and expressed as a percentage of CAHF. Significance is expressed as *p<0.05 vs. obese males.
RPP: rate pressure product; (dp/dt)max: index of myocardial contraction velocity; LVDevP: left ventricular developed pressure; LVEDP: left ventricular end
diastolic pressure; LVESP: left ventricular end systolic pressure; CAHF: critical acute heart failure; RAHF: recovery acute heart failure; Sig.: significance;
ns: not significant.
https://doi.org/10.1371/journal.pone.0179509.t012
Table 13. AHF ex vivo model–underlying features.
Baseline
stabilization
CAHF RAHF
Simulated metabolism
Normal glucose Low glucose Normal glucose
No FAs FAs FAs
(Normal fuel) (Push towards FAO) (Choice in fuel)
Induced functional parameters
Normal pressure Low pressure Normal pressure
Normal perfusion Low perfusion Normal perfusion
Paced Unpaced Paced
Expected function under simulated conditions
Normal Critically low Increased function (recovery)
Expected function with TMZ treatment
Restore equilibrium back to glucose
utilization
Favors the equilibrium towards glucose
utilization
FAs: fatty acids; FAO: Fatty acid β-oxidation
https://doi.org/10.1371/journal.pone.0179509.t013
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in the two estrus phases may be due to varying treatment patterns as a result of sex hormone
differences.
Limitations to the current study include the lack of measurement of steroid levels and
should ideally include suitable methods to evaluate estradiol and progesterone concentrations.
Additionally, inclusion of an experimental group where TMZ is administered during the
CAHF phase followed by a) a ‘‘wash out” period and b) a non-TMZ RAHF phase would have
strengthened our findings. Based on our results showing that some females are resistant to
TMZ treatment, additional evaluation of increased drug dosages in this instance may eventu-
ally trigger cardioprotection. Future in vivo studies should also evaluate acute TMZ adminis-
tration to db/db mice and its effects on cardiac metabolism and heart function.
Conclusions
We have successfully established a novel ex vivo mouse AHF model and these data reveal that
TMZ elicits negligible effects on heart function during the CAHF phase, but that it results in
significant recovery for both male and obese female hearts when administered during the
RAHF phase. Our findings demonstrate that there were no differences between lean and obese
male hearts, while lean females are at a clear functional recovery advantage over lean males.
Here the luteal group displayed superior functional improvement and this is likely due to an
innate coping mechanism that is lost with obesity. Thus TMZ emerges as a worthy therapeutic
target to consider for AHF treatment in normal and obese-diabetic individuals (for both
sexes), but only when administered during the recovery phase and not during the very acute
stages.
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